[breadcrumb_custom]

Buy, Sell Or Hold Nurix Therapeutics Inc (NASDAQ:NRIX) At $8.85?

In last trading session, Nurix Therapeutics Inc (NASDAQ:NRIX) saw 0.33 million shares changing hands with its beta currently measuring 1.87. Company’s recent per share price level of $8.85 trading at $0.23 or 2.67% at ring of the bell on the day assigns it a market valuation of $429.23M. That closing price of NRIX’s stock is at a discount of -58.08% from its 52-week high price of $13.99 and is indicating a premium of 52.32% from its 52-week low price of $4.22. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.52 million shares which gives us an average trading volume of 728.94K if we extend that period to 3-months.

Nurix Therapeutics Inc (NASDAQ:NRIX) trade information

Upright in the green during last session for gaining 2.67%, in the last five days NRIX remained trading in the green while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $8.85 price level, adding 1.45% to its value on the day. Nurix Therapeutics Inc’s shares saw a change of -14.24% in year-to-date performance and have moved 8.72% in past 5-day. Nurix Therapeutics Inc (NASDAQ:NRIX) showed a performance of -10.33% in past 30-days. Number of shares sold short was 7.01 million shares which calculate 6.95 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Nurix Therapeutics Inc (NRIX) estimates and forecasts

Statistics highlight that Nurix Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -6.15% of value to its shares in past 6 months, showing an annual growth rate of 35.31% while that of industry is 15.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 34.50% in the current quarter and calculating -6.70% decrease in the next quarter. This year revenue growth is estimated to rise 115.30% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $22.26 million for the same. And 5 analysts are in estimates of company making revenue of $17.27 million in the next quarter that will end on Feb 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -94.23% during past 5 years.

NRIX Dividends

Nurix Therapeutics Inc is more likely to be releasing its next quarterly report in March and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

On Key

Related Posts